Morton’s Neuroma Treatments: Conservative Care, Surgery or Injections

Ross A. Hauser, MD, Danielle R. Steilen-Matias, MMS, PA-C

Many of the foot pain patients that we see in our clinic, come in with an extensive history of what they did to try to treat their foot problems. They are extensive because many of these people work at jobs that require a lot of physical demand including being on their feet all day, or they are competitive or recreational runners who are still trying to run through the pain. Some patients are women who have foot pain and numbness after a lifetime of tight shoes and high heels. Women are also more prone to suffering from Morton’s Neuroma if they are overweight as suggested in research published in March 2020 in the European Journal of Neurology. (1)

These patients will tell us about foot pain accompanied by tingling or numbness or a sensation like they have a pebble in their shoe. They will further describe a pain in the center of their foot that becomes acute upon “foot strike,” or “putting weight on it.” Sometimes they will describe a snapping or cracking sensation and a shooting burning kind of nerve pain. When they describe these symptoms to us, we start to suspect Morton’s Neuroma. This means that the nerves that travel in between the bones of the foot have become impinged or squeezed.

Morton’s Neuroma: Foot bone instability, which may be a result of ligament or tendon weakness, can cause a thickening of tissue around a digital nerve. Foot bones collide and compress the nerves.

The bones in the foot can become unstable objects, wandering around the foot and compressing nerves due to weakness and loss of strength and elasticity in the connective tissues, the tendons, ligaments, and fascia that are holding the bones and feet together. When the connective tissue is damaged wandering bones collide, squeezing everything between them including the nerves. If those bones are moving so much that they are putting continuous pressure on the nerves, the nerve will swell. Thus, Morton’s neuroma occurs in a digital nerve in the foot, often between the third and fourth toes.

In this video, Ross Hauser, MD. describes instability in the metatarsal joints as a common cause of foot problems including Morton’s Neuroma.

Summary transcript:

  • On physical examination, when instability in the metatarsal joints is suspected, we commonly hear a clicking sound when the toes or the metatarsal joints are compressed, or in this examination, gently squeezed together. When we hear the clicking sounds, this is our first sign that there is instability in the foot causing hypermobility in the joint. This compression action is called a Mulder’s Sign, the noise of a Mulder’s Click.
  • At 1:07 of the video an ultrasound examination displays the foot instability.
  • We treat this problem with simple dextrose Prolotherapy. The treatment is explained in detail below. Prolotherapy addresses the instability by strengthening the connective tissue, the ligaments, that hold the bones in place. Typical 2 – 5 treatments will be needed to resolve Morton’s Neuroma.
  • As we mentioned above, Morton’s neuroma is typically diagnosed from the symptom of burning pain in a toe or toes. Although this burning pain and numbness may be due to nerve entrapment, it may also find its origins in problems of damaged ligaments and tendons.
Mulder’s sign. A click can be felt when squeezing the metatarsal heads together at the place where the interdigital nerve is being compressed. This is a sign of instability in the metatarsal joint.
Mulder’s sign. A click can be felt when squeezing the metatarsal heads together at the place where the interdigital nerve is being compressed. This is a sign of instability in the metatarsal joint.

Clinical examination versus MRI and ultrasound

In an October 2023 study in The Journal of foot and ankle surgery, (23) doctors at the University of Queensland investigated whether clinical examination is as sensitive as ultrasound and magnetic resonance imaging (MRI) in the diagnosis and localization of symptomatic interdigital neuroma. The sensitivity of clinical assessment (the ability of the clinician) to accurately diagnose and place an interdigital neuroma in the correct space was calculated as 96.5%. The most common preoperative clinical feature was pain (99.2%).

The calculated sensitivity for ultrasound to accurately diagnose an interdigital neuroma was 83.6%, and to correctly locate neuroma was 79.5% respectively. The calculated sensitivity for MRI to accurately diagnose an interdigital neuroma was 93.6%.

The point here was that pain was the dominating feature and that if a clinician follows the foot and finds the pain point, treatments can be better planned.

A typical patient that we suspect of having Morton’s Neuroma will usually describe their medical history as:

  • A series of x-rays, scans, ultrasounds, and MRIs basically painted an “inconclusive picture.”
  • Trips to the general practitioner, referral to the podiatrist, referral to the orthopedic surgeon, and the ultimate recommendation for surgery.
  • To delay or see if surgery can be avoided, a series of “conservative care recommendations” are offered.
    • Avoid walking barefoot.
    • A steady regiment of icing.
    • Shoe inserts and pads.
    • New shoes, especially extra wide shoes.
    • Walking boot.

While some of these recommendations may be effective in providing symptom relief, they may not do enough. Many patients have graduated to more extensive conservative care treatments. This would include:

  • Physical therapy.
  • Shockwave therapy.
  • Cortisone.

These conventional therapies, and more including rest, weight loss, massage therapy, manipulation, analgesics, non-steroidal anti-inflammatory drugs, anti-depressant medications, and trigger point injections often result in residual pain for the patients.

Why is the treatment of Morton’s Neuroma ineffective? “The condition is degenerative rather than neoplastic”

As pointed out Morton’s Neuroma can be a controversial diagnosis. This is suggested again in a January 2023 update (2) to the United States Library of Congress’ medical publication STAT PEARLS.  “Morton’s neuroma is a compressive neuropathy of the forefoot interdigital nerve. Neuropathy is chiefly due to compression and irritation at the plantar aspect of the transverse intermetatarsal ligament. It is not a true neuroma as the condition is degenerative rather than neoplastic (being caused by abnormal tissue growth as in cysts or tumors or other overgrowths).

Many people get relief from the various treatments we mentioned above. This article is for people who did not get relief or have varying diagnoses that may describe a common foot problem. Those being as described in the above publication: “Morton metatarsalgia, interdigital neuritis, Morton entrapment, interdigital neuralgia, interdigital neuroma, interdigital nerve compression syndrome, and intermetatarsal neuroma.”

It is quite common for people with the diagnosis of a neuroma, or nerve entrapment, to undergo multiple surgeries attempting to alleviate the entrapment. One individual came to us with a history of 15 surgeries. Multiple surgeries occur primarily because most physicians incorrectly believe numbness is equated with a pinched nerve. Ligament and tendon weakness in the limb also cause chronic numbness in an extremity.

Despite years of experimental research and clinical investigation, the painful neuroma has remained difficult to prevent or to treat successfully when it occurs. More than 150 physical and chemical methods for treating neuromas have been utilized including suturing, covering with silicone caps, injecting muscle or bone with chemicals such as alcohol, and many others.

Morton’s Neuroma treatments: Cortisone injections

Cortisone is given to reduce the inflammation of the nerve. While successful cortisone injections have side effects. Among the most common are skin atrophy, skin depigmentation, and damage to soft tissue around the neuroma such as the ligaments.

In November 2019, foot specialists from the University Hospitals of Leicester in the United Kingdom published a comparison review of  “nine different non-operative treatment modalities (for Morton’s Neuroma); Corticosteroid injection, Alcohol injection, Extra-corporeal Shockwave therapy (ESWT), Radiofrequency Ablation (RFA), Cryoablation, Capsaicin injection, Botulinum toxin, Orthosis, and YAG Laser Therapy, in the European Journal of Foot and Ankle Surgery. (3) When compared against the other 8 treatments the researchers: “would recommend the use of corticosteroid injections to treat Morton’s neuromas.” This does not suggest that cortisone is very effective, just better than these other treatments. Cortisone can be very effective for some, but the treatments may not be effective for others. How can you tell?

Related research and comparisons: In the research above, cortisone is said to have provided the best results. Here are the most cited studies suggesting the benefits of the other treatments.

Botulinum toxin

A 2013 study published in the Clinical drug investigation (4) found injection with Botulinum toxin to be of possible usefulness to relieve the pain and improve function in Morton neuroma. This paper has been cited by over 50 other papers with varying degrees of success suggested.

Capsaicin injection

A June 2016 double-blind placebo-controlled study from Johns Hopkins University School (5)  tested the effectiveness and safety of a single 0.1 mg dose of capsaicin vs placebo injected into people diagnosed with Morton’s neuroma. At one and four weeks after injection, a significant decrease in pain was observed in the capsaicin-injected group versus the placebo group.  Improvements in function and reductions in oral analgesic use were also seen in the capsaicin-treated group.

Cryoablation

Cryoablation is the use of cold therapy to freeze or freeze-burn the nerves. An October 2016 study (6) looked at cryoablation outcomes in 20 Morton’s neuroma patients. The researchers found high patient satisfaction in the group after the procedure, reduced risk of “stump neuroma” syndrome, and good patient tolerance on an outpatient basis.

Ultrasound-guided radiofrequency ablation (RFA)

An October 2019 paper in the journal Clinical Radiology (7) assessed the effectiveness and safety of ultrasound-guided radiofrequency ablation (RFA) for the treatment of symptomatic Morton’s neuroma (22 neuromas were treated). At 8 months in, 89% of treated patients were satisfied with the procedure outcome. No significant adverse effects were recorded. The research concludes: “Ultrasound-guided radiofrequency ablation is safe, with excellent initial results in the treatment of symptomatic Morton’s neuroma.

Morton’s Neuroma Cortisone injection side-effects and short-term relief outcomes

We are going to start a seven-year assessment of research focusing on cortisone injections and Morton’s neuroma.

In 2016 doctors in the United Kingdom (8) assessed patients who received a cortisone injection for their Morton’s neuroma problem. They were looking for factors in the treatments that would allow them to predict who would need more treatments within 2 years of the single ultrasound-guided corticosteroid injection the patients received.

Of the treated feet:
54 patients (57 feet) were reviewed:

  • 51% required further treatment within 2 years (11 repeat injections, 18 surgical excisions).
    • Larger neuromas and younger patients were more likely to need further treatments.

“(29.85%) eventually underwent surgery after receiving corticosteroid injections due to persistent pain.”

In June 2021 doctors publishing in the journal Clinics in Orthopedic Surgery (9) offered an assessment of cortisone injections for Morton’s Neuroma. The highlights of their findings were as noted:

  • “Corticosteroid injections showed a satisfactory clinical outcome in patients with Morton’s interdigital neuroma although (the researchers) found that 140 subjects out of 469 study patients (29.85%) eventually underwent surgery after receiving corticosteroid injections due to persistent pain.”

The initial success of treatment:

  • “At three to twelve months of follow-up, corticosteroid injections provided satisfactory outcomes based on (standard) satisfaction scores.
  • Standard pain scores showed that maximal pain reduction appeared at 1 week to 3 months.
  • After 3 months, the cortisone benefits ended as patient-reported pain scores increased again by 6 months.
  • Regarding multiple steroid injections, three or four injections over 6 months seem to be safe and avoid unwanted complications, although there was a lack of good-quality studies about multiple injections. Skin depigmentation and skin or fat pat atrophy were reported as minor complications.

A single corticosteroid injection appears to have a beneficial short- to medium-term effect on Morton’s neuroma pain.

A July 2021 paper in the Journal of the American Podiatric Medical Association (10) sought to examine and compile evidence relating to the effectiveness of corticosteroid injection for Morton’s neuroma. To do this, researchers assessed previously reported studies where randomized and nonrandomized controlled trials of a single corticosteroid injection for Morton’s neuroma pain were investigated. The primary outcome was Morton’s neuroma pain as measured by any standard validated pain scale.

  • Ten studies involving 695 participants were included.
  • Of the included studies, five compared corticosteroid injection to usual care, one compared corticosteroid injection to local anesthetic alone, one compared ultrasound-guided to non-ultrasound-guided injections, three compared corticosteroid injections to surgery, one compared small to large neuromas, six assessed patient satisfaction, four measured adverse events, one studied return to work, and one examined failure of the corticosteroid injection to improve pain.
  • Overall, these studies identified a moderate short- to medium-term benefit of corticosteroid injections on the primary outcome of pain and a low adverse event rate.

Conclusions: A single corticosteroid injection appears to have a beneficial short- to medium-term effect on Morton’s neuroma pain. It appears superior to usual care, but its superiority to local anesthetic alone is questionable, and it is inferior to surgical excision.

Diminished short-term pain after injection in 73% of their patients

A June 2020 study in the journal Pain and Therapy (11) explored different injection techniques for Morton’s Neuroma. In the discussion about cortisone, the researchers, led by Harvard Medical School, noted:

“Steroid treatment is commonly used to alleviate symptoms (of Morton’s Neuroma) along with changes in footwear and stretching. Principal findings (in a previous study) showed that corticosteroid injections with local anesthetics did improve symptoms temporarily between the experimental and control groups. However, the beneficial effects diminished over a short period of time. In addition to the short-term effects, (the research) also noted diminished short-term pain after injection in 73% of their patients. However, there were side effects that resulted in pain in the injection site, skin lesions, and tissue alterations consisting of “steroid flare,” tissue atrophy, and pigment alterations.”

Medium-term results of corticosteroid injections for Morton’s neuroma

In April 2021, doctors at the University Hospitals of Leicester published their findings in the journal Foot and ankle international (12) on their evaluation of the medium-term results of corticosteroid injections for Morton’s neuroma.

In this study, Forty-five neuromas in 36 patients were injected with a single corticosteroid injection either with or without ultrasound guidance.

  • At an average follow-up of 4.8 years, the original corticosteroid injection remained effective in 36% (16 patients). In these cases, pain scores demonstrated significantly better than preintervention pain scores.
  • The remaining cases underwent either a further injection or surgery.
    • Fifty-five percent of the 11 neuromas that received a second injection continued to be asymptomatic in the medium term.
    • Overall, 44% (20 patients) of the original group underwent surgical excision by the medium-term follow-up.

Conclusion: “Corticosteroid injections for Morton’s neuroma remained effective in over a third of cases for up to almost 5 years. A positive outcome at 1 year following a corticosteroid injection was reasonably predictive of a prolonged effect from the injection.”

“Corticosteroid injections showed a satisfactory clinical outcome . . . in spite of almost 30% of included subjects eventually underwent operative treatment.”

A January 2022 study in the journal Foot and Ankle Orthopaedics (13) suggested: “Corticosteroid injections showed a satisfactory clinical outcome in patients with Morton’s interdigital neuroma in spite of almost 30% of included subjects eventually underwent operative treatment.” The researchers also made a recommendation that future studies about the safety and effectiveness of multiple injections at the same site are highly necessary.

Is cortisone the best we can do? How about burning out the nerves?

In February 2019 researchers wrote in the Journal of Foot and Ankle Research (14)  “Corticosteroid injections and manipulation/mobilization are the two interventions with the strongest evidence for pain reduction, however high-quality evidence for a gold standard intervention was not found.” This was also a comparison against extracorporeal shockwave therapy, Sclerosing (alcohol injections), Botox injections, radiofrequency ablation, and cryoneurolysis. The alcohol injections that burn out the nerve were found more effective in another study published in the journal Foot and Ankle Surgery, April 2019 (11). Here the researchers noted “Needle-electrode guided percutaneous alcoholization is an outpatient, minimally invasive procedure with a low rate of complications. Better results of those obtained with traditional conservative treatments and comparable with those reported with other alcohol injections or surgical nerve excision were observed.”

Physical or Fascial Manipulation Technique for Morton’s Neuroma

A July 2021 paper in the International Journal of Environmental Research and Public Health (15) wrote: “There is currently no gold standard of treatment (for Morton’s Neuroma); nonoperative management commonly involves manual therapies, orthoses therapy, and infiltrative (injection) techniques, while surgery is indicated after failure of conservative measures.” In their study, the researchers presented a preliminary study on the effectiveness of the Fascial Manipulation technique, a noninvasive manual therapy, focused on the release of the deep fascia, reducing its stiffness.

  • Nine patients, among 28 recruited initially, completed the manual therapy sessions and relative follow-up points.
  • This non-invasive pain treatment led to a significant improvement in pain and function scores.
  • At the three-month follow-up, both scores decreased slightly, remaining however superior to the pre-treatment values.
  • Conclusions: “Despite the small size of the case series, this pilot study is unique in supporting Fascial Manipulation in the nonoperative treatment of Morton’s Neuroma). Further studies are needed with a large group of gender-balanced patients to confirm the encouraging results obtained.”

Moving onto surgery when cortisone or conservative care did not help Morton’s Neuroma symptoms

In June 2017, hospital and university researchers in Barcelona published their findings on cortisone in the medical journal Foot and Ankle International. (16)

Here they write that the effectiveness of corticosteroid injection for the treatment of Morton’s neuroma is unclear and to see if they could make it clearer that reviewed 41 patients with a diagnosis of Morton’s neuroma.

  • The 41 patients were randomized to receive 3 injections of either a corticosteroid plus a local anesthetic or a local anesthetic alone.
  • The results they found were that there were no significant between-group differences in terms of pain and function improvement at 3 and 6 months after treatment completion in comparison with baseline values.
  • At the end of the study, 17 (48.5%) patients requested surgical excision of the neuroma: 7 (44%) in the experimental group and 10 (53%) in the control group.
  • The injection of a corticosteroid plus a local anesthetic was not superior to a local anesthetic alone in terms of pain and function improvement in patients with Morton’s neuroma.

Surgical treatment for Morton’s Neuroma has been problematic with poor results and complications

Doctors at the Royal Infirmary of Edinburgh (17) wrote in the Bone and Joint Journal of examined patients who had excision of Morton’s neuroma. (The removal of the Neuroma and the nerve it was attached to – neurectomy).

Results:

  • 49.5% of patients reported their overall satisfaction as excellent
  • 29.3% of patients reported their overall satisfaction as good
  • 8.1% of patients reported their overall satisfaction as poor
  • 2% of patients reported their overall satisfaction as very poor
    • Only 63 patients (63%) were pain-free at follow-up:
    • in eight patients (8.1%), the score worsened.

There was no statistically significant difference in outcome between surgery on single or multiple sites. However, pain scores were significantly worse after repair or revision surgery

The patient-reported outcomes after resection of symptomatic Morton’s neuroma are acceptable but may not be as good as earlier studies suggest. Surgery at several sites can be undertaken safely but caution should be exercised when considering revision surgery.”

Doctors at the University of Tennessee suggest that approximately 80% of patients require surgical excision of neuromas for symptom relief. Although 50% to 85% of patients obtain relief after primary excision, symptoms may recur because of an incorrect diagnosis, inadequate resection, or adherence of pressure on a nerve stump neuroma. They suggest counseling patients on the increased possibility of more than one surgery. (18It should be pointed out that the title of this research paper is “The recurrent Morton Neuroma: what now?” 

Following this line of research was a January 2021 paper published in the Clinics in Podiatric Medicine and Surgery (19)  which noted: “While within the literature, there is a high success rate with primary neurectomy procedures, the risk of recurrence of symptoms or “stump neuromas” remains difficult to treat and can lead to debilitating pain.” The authors provided updates on a nerve-sparing, microneurosurgical, procedure for the management of Morton’s neuromas.

Operative treatments other than neurectomy for Morton’s neuroma

In October 2021, doctors writing in the journal Foot and ankle surgery (20) examined the effectiveness of operative treatments other than neurectomy for Morton’s neuroma as these other surgical incursions success remain debatable despite several reported studies. The researchers noted that although a number of studies with high levels of evidence are limited, they could still divide them into four surgical-type categories:

  • Neurolysis with or without nerve transposition (moving the nerve to an area where it is less likely to be compressed),
  • minimally invasive nerve decompression, (releasing the transverse intermetatarsal ligament)
  • metatarsal osteotomy, (cutting the metatarsal bone) and,
  • additional procedures after nerve transection or neurectomy.

All categories showed reliable outcomes except minimally invasive nerve decompression. The proportion of postoperative neurogenic symptoms was lower with neurolysis than with neurectomy.

The researchers concluded: “Whether the alternative procedures were superior to neurectomy remains unclear as the number of good quality studies was limited. The proportion of postoperative neurogenic symptoms was lower with neurolysis (burning the nerve) than with neurectomy. Furthermore, performing simultaneous dorsal transposition (moving) of the nerve along with neurolysis is more recommended than neurolysis alone. Surgeons should be more careful with minimally invasive deep transverse intermetatarsal ligament release and metatarsal shortening osteotomy as their effectiveness remains inconclusive. Finally, we strongly recommend performing intramuscular embedding or intermuscular transposition of the nerve-cutting end if neurectomy or nerve transection is inevitable. (Put the nerve is a place that is more accessible for the next surgery.)”

The optimal treatment of symptomatic Morton’s neuroma remains unclear

A December 2022 paper in the International Orthopaedics (21) also looked at surgical options.

“The optimal treatment of symptomatic Morton’s neuroma remains unclear; conservative methods are sometimes ineffective and neurectomy has significant rates of patient dissatisfaction.” In this study, doctors assessed the outcome of a minimally invasive distal metatarsal metaphyseal osteotomy (bone remodeling) and percutaneous release of the deep transverse metatarsal ligament (DTML) in patients with Morton’s neuroma.

  • 27 patients (29 feet) diagnosed with Morton’s neuroma underwent minimally invasive distal metatarsal metaphyseal osteotomy (bone remodeling) and percutaneous release of the deep transverse metatarsal ligament (DTML) in patients with Morton’s neuroma were followed up for a minimum of two years. The majority of patients (89.7%) were satisfied and considered the procedure outcome as excellent or good in reducing pain and improving function.

Our Research on Prolotherapy for Morton’s Neuroma

This is a summary of research from Caring Medical investigators published in the medical journal Foot and Ankle Online Journal. (22)

This study investigates the effectiveness of Dextrose Prolotherapy injections on a group of patients with “Morton’s neuroma.”

Study Results

The patients in the study had reported other previous treatments prior to beginning the Prolotherapy treatments.

Some patients had tried:

  • wide-toed shoes,
  • orthotics,
  • padding,
  • chiropractics,
  • acupuncture,
  • and steroid injections.

Some patients had had MRI and radiographic diagnoses. One of seventeen had seen a podiatrist. A physician told three patients that surgery was required, but only one had surgery to remedy the pain on the other foot.

The average length of time patients experienced the pain of Morton’s neuroma was 20 months before entering the clinic.

  • Patients received an average of 3.7 Prolotherapy treatments.

Before treatment patients were asked to rate their pain levels on a scale of 0 to 10—with 0 being no pain and 10 being severe crippling pain (this scale is referred to as VAS).

All 17 patients reported pain as a symptom. Thus, patients were asked to report pain levels before and after Prolotherapy in these four categories:

1) pain at rest;

2) pain with normal activities;

3) pain with exercise, and

4) pain while walking barefoot.

Concerning 1): Pain at rest:

Prior to Prolotherapy treatment, pain levels averaged VAS 4.68. None of the patients had a starting pain of less than three.

  • After Prolotherapy treatment, VAS pain levels averaged 0.95 (less than 1 out of 10).
  • Significant improvement was recorded.

Concerning 2): Pain with normal activity and mobility:

Prior to Prolotherapy treatment, 15 of the 17 participants reported walking with some degree of pain, and a VAS pain level of 6.89.

  • Eleven of 17 patients were unable to walk fifty feet without pain;
  • 14 of 17 could not walk a half-mile without pain.
  • Four of 17 patients reported an inability to walk barefoot.
  • After Prolotherapy, all patients reported improvements in walking without pain and a VAS pain level of 1.89.
  • Fourteen of the 17 participants walked normally again and rated their pain relief at greater than 74%.
  • Sixteen of the 17 could walk one block or more.

Concerning 3): Pain with exercise:

Prior to Prolotherapy, 15 of the 17 patients reported decreased ability to exercise, and a VAS pain level of 7.27.

  • Of those 15, eight were totally compromised and unable to exercise;
  • five were moderately (only 30 to 60 minutes possible) to severely compromised (only 0 to 30 minutes possible).

Nearly half of the patients were totally compromised in their athletic abilities prior to treatment.

  • After Prolotherapy, 5 of the 17 patients reported being able to exercise as much as they wanted without impediments and with satisfaction, with a VAS pain level of 1.73.

Other physical improvements occurred, notably, decreases in stiffness and numbness (burning). Thirteen to 14 patients reported a 100% improvement in the activities of daily living that continued to the end of the study. None reported an inability to exercise.

Concerning 4): Pain while walking in bare feet:

  • Prior to Prolotherapy treatment, 10 of 17 patients could not walk barefoot without severe pain at levels eight, nine, or ten, and an average VAS pain level of 6.47.

Furthermore, 12 of 17 patients could walk less than 50 feet before they experienced noticeable pain, with or without shoes. Only 3 of the 17 patients could walk more than a half-mile without pain.

  • After Prolotherapy, all patients had a pain level of four or less walking barefooted and a VAS pain level of 1.65. As for walking distances without pain, all patients could walk at least one block or more. One patient was restricted to walking between 50 feet and one block. Among the 19 treated feet of the 17 patients in the study, eighteen feet could manage walking a half-mile or more, and eight of the treated feet reported no walking restrictions.

When comparing the four previous categories before and after Prolotherapy, all reached a statistically significant outcome.

This study justifies the desirability and use of Prolotherapy for Morton’s neuroma pain. Future studies need to further substantiate these findings, especially if Prolotherapy enables Morton’s neuroma sufferers to avoid surgery and its possible adverse effects.

Although a study with more patients in a controlled empirical setting is needed to document the efficacy of Dextrose Prolotherapy, this treatment should be considered, based on the substantial advantages and minimal drawbacks (e.g., aversion to needles), as well as the reduced risks and increased rewards of Prolotherapy over conventional treatments.

Demonstration of Prolotherapy treatment for Morton’s Neuroma

In this video, Danielle Matias, MMS, PA-C demonstrates and explains the Prolotherapy treatment for Morton’s Neuroma

Summary highlights of the video are below:

Summary highlights

  • Typically patients with Morton’s Neuroma get pain right in the ball of their feet. They may even have pain or numbness that radiates into their toes.
  • Many patients we see have had cortisone shots or surgery and nothing has made their situation better and in fact, their situation is getting worse.
  • In the treatment, injections are given at the ligament attachments at the top and bottom of the ball of the foot. The Prolotherapy injections help restore stability in the foot and prevent hypermobility and the pressure the foot bones are exerting on the nerves. Removing this pressure by getting the bones back where they belong will give the nerves a better chance of healing and restore natural foot stability.
  • The patient in this video tolerates the treatments very well, typically 3 – 6 treatments are needed with more treatments that may be necessary for patients who have cortisone or surgical history.

Summary and contact us. Can we help you?

Most chronic foot pain and numbness are not primarily due to a nerve being pinched but due to weakness in the ligaments and soft tissue structures that support the ball of the foot and the arch. Prolotherapy injections start these areas to grow new and stronger tissue. Once this tissue gains normal strength the pain, numbness, and disability normally stop. If it does not, the nerve entrapment can be “unpinched” quickly and nonsurgically with Nerve Release Injection Therapy (NRIT). (Please see our article on Nerve Release Injection Therapy). In our office, we frequently combine dextrose Prolotherapy with  Nerve Release Injection Therapy (NRIT) and/or Lyftogt Perineural Injection Therapy for nerve-related pain. This combined approach works well to correct the underlying joint instability, as well as free up and nourish the entrapped nerve.

While the exact cause of Morton’s neuroma (MN) is still debated, our research confirms Prolotherapy not only reduces levels of pain for patients with Morton’s Neuroma but also enhances other quality-of-life concerns.

In our study as discussed above, we found that dextrose Prolotherapy was extremely effective at improving a number of pain factors: pain at rest; pain with normal activities; pain with exercise; pain while walking barefoot. Patients’ subjective experience of pain offers the best measure for statistical accuracy, and all patients in our study reported pain as a symptom. Patients were additionally asked about numbness levels and stiffness.

This prospective, non-controlled study demonstrated that Prolotherapy decreases pain and improves the quality of life for patients with Morton’s neuroma, which was unresolved by previous therapies, medications, and interventions. Prolotherapy provided relief of at least 74% for 14 out of 17 of the patients at least six months after their last treatment. Two out of three patients who were told they needed surgery prior to Prolotherapy, felt sufficient pain relief with Prolotherapy and were able to avoid surgery. After the study period, patients experienced an overall improvement in range of motion, ability to walk, and exercise, as well as relief of stiffness and numbness/burning.

We hope you found this article informative and that it helped answer many of the questions you may have surrounding your foot problems.  If you would like to get more information specific to your challenges of peroneal tendon injury and ankle instability, please email us: Get help and information from our Caring Medical staff

 

Subscribe to our newsletter

References:

1 Martínez‐Aparicio C, Jääskeläinen SK, Puksa L, Reche‐Lorite F, Torné‐Poyatos P, Paniagua Soto J, Falck B. Constitutional risk factors for focal neuropathies in patients referred for electromyography. European journal of neurology. 2019 Nov 6.
2 Munir U, Tafti D, Morgan S. Morton Neuroma. StatPearls [Internet]. 2023 Jan. Treasure Island (FL): StatPearls Publishing [Google Scholar]
3 Thomson L, Aujla RS, Divall P, Bhatia M. Non-surgical treatments for Morton’s neuroma: A systematic review. Foot and Ankle Surgery. 2019 Nov 2. [Google Scholar]
4 Climent JM, Mondéjar-Gómez F, Rodriguez-Ruiz C, Diaz-Llopis I, Gómez-Gallego D, Martín-Medina P. Treatment of Morton neuroma with botulinum toxin A: a pilot study. Clinical drug investigation. 2013 Jul;33:497-503. [Google Scholar]
5 Campbell CM, Diamond E, Schmidt WK, Kelly M, Allen R, Houghton W, Brady KL, Campbell JN. A randomized, double-blind, placebo-controlled trial of injected capsaicin for pain in Morton’s neuroma. Pain. 2016 Jun 1;157(6):1297-304. [Google Scholar]
6 Cazzato RL, Garnon J, Ramamurthy N, Tsoumakidou G, Caudrelier J, Thenint MA, Rao P, Koch G, Gangi A. Percutaneous MR-guided cryoablation of Morton’s neuroma: rationale and technical details after the first 20 patients. Cardiovascular and interventional radiology. 2016 Oct;39:1491-8. [Google Scholar]
7 Shah R, Ahmad M, Hanu-Cernat D, Choudhary S. Ultrasound-guided radiofrequency ablation for treatment of Morton’s neuroma: initial experience. Clinical Radiology. 2019 Oct 1;74(10):815-e9. [Google Scholar]
8 Mahadevan D, Salmasi M, Whybra N, Nanda A, Gaba S, Mangwani J. What factors predict the need for further intervention following corticosteroid injection of Morton’s neuroma? Foot Ankle Surg. 2016 Mar;22(1):9-11. [Google Scholar]
9 Choi JY, Lee HI, Hong WH, Suh JS, Hur JW. Corticosteroid injection for Morton’s interdigital neuroma: A systematic review. Clinics in orthopedic surgery. 2021 Jun;13(2):266. [Google Scholar]
10 Edwards SR, Fleming S, Landorf KB. Efficacy of a Single Corticosteroid Injection for Morton’s Neuroma in Adults: A Systematic Review. Journal of the American Podiatric Medical Association. 2021 Jul 1;111(4):Article_13. [Google Scholar]
11 Urits I, Smoots D, Franscioni H, Patel A, Fackler N, Wiley S, Berger AA, Kassem H, Urman RD, Manchikanti L, Abd-Elsayed A, Kaye AD, Viswanath O. Injection Techniques for Common Chronic Pain Conditions of the Foot: A Comprehensive Review. Pain Ther. 2020 Jun;9(1):145-160. doi: 10.1007/s40122-020-00157-5. Epub 2020 Feb 27. PMID: 32107725; PMCID: PMC7203280. [Google Scholar]
12 Hau MY, Thomson L, Aujla R, Madhadevan D, Bhatia M. Medium-Term Results of Corticosteroid Injections for Morton’s Neuroma. Foot & Ankle International. 2021 Apr;42(4):464-8. [Google Scholar]
13 Choi JY, Hong WH, Kim MJ, Chae SW, Suh JS. Operative treatment options for Morton’s neuroma other than neurectomy− a systematic review. Foot and Ankle Surgery. 2021 Oct 27. [Google Scholar]
14 Matthews BG, Hurn SE, Harding MP, Henry RA, Ware RS. The effectiveness of non-surgical interventions for common plantar digital compressive neuropathy (Morton’s neuroma): a systematic review and meta-analysis. Journal of foot and ankle research. 2019 Dec 1;12(1):12. [Google Scholar]
15 Biz C, Stecco C, Fantoni I, Aprile G, Giacomini S, Pirri C, Ruggieri P. Fascial Manipulation Technique in the Conservative Management of Morton’s Syndrome: A Pilot Study. International journal of environmental research and public health. 2021 Jan;18(15):7952. [Google Scholar]
16 Lizano-Díez X, Ginés-Cespedosa A, Alentorn-Geli E, Pérez-Prieto D, González-Lucena G, Gamba C, de Zabala S, Solano-López A, Rigol-Ramón P. Corticosteroid Injection for the Treatment of Morton’s Neuroma: A Prospective, Double-Blinded, Randomized, Placebo-Controlled Trial. Foot & Ankle International. 2017 Jun 1:1071100717709569. [Google Scholar]
17 Bucknall V, Rutherford D, MacDonald D, Shalaby H, McKinley J, Breusch SJ. Outcomes following excision of Morton’s interdigital neuroma: a prospective study. Bone Joint J. 2016 Oct;98-B(10):1376-1381. [Google Scholar]
18 Richardson DR, Dean EM. The recurrent Morton neuroma: what now?  Foot Ankle Clin. 2014 Sep;19(3):437-49. doi: 10.1016/j.fcl.2014.06.006. Epub 2014 Jul 17. [Google Scholar]
19 Patel NR, Oexeman S, Rodriguez-Collazo ER. An Updated Nerve Sparing Surgical Technique for Addressing Morton’s Neuroma. Clinics in Podiatric Medicine and Surgery. 2021 Jan 1;38(1):e24-30. [Google Scholar]
20 Choi JY, Hong WH, Kim MJ, Chae SW, Suh JS. Operative treatment options for Morton’s neuroma other than neurectomy− a systematic review. Foot and Ankle Surgery. 2022 Jun 1;28(4):450-9. [Google Scholar]
21 Sato G, Ferreira GF, Sevilla D, Oliveira CN, Lewis TL, Dinato MC, Pereira Filho MV. Treatment of Morton’s neuroma with minimally invasive distal metatarsal metaphyseal osteotomy (DMMO) and percutaneous release of the deep transverse metatarsal ligament (DTML): a case series with minimum two-year follow-up. International Orthopaedics. 2022 Dec;46(12):2829-35. [Google Scholar]
22 Hauser RA, Feister WA, Brinker DK. Dextrose Prolotherapy Treatment for Unresolved “Morton’s Neuroma” Pain
23 Franco H, Pagliaro T, Sparti C, Walsh HJ. Comparing clinical examination and radiological evaluation in the preoperative diagnosis and location of symptomatic Interdigital (Morton’s) Neuroma. The Journal of foot and ankle surgery: official publication of the American College of Foot and Ankle Surgeons.:S1067-2516. [Google Scholar]

This article was updated July 31, 2023

 

Get Help Now!

You deserve the best possible results from your treatment. Let’s make this happen! Talk to our team about your case to find out if you are a good candidate.